Acetylcysteine

Acetylcysteine

SCHEMBL893717

CC(=O)NC(CS)C(=O)O.NCCCCC(N)C(=O)O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Acetylcysteine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 1/20 0.62
PTGS1 known ✓ P23219 1/20 0.41
BLM P54132 2/20 0.62
KDM4E B2RXH2 1/20 0.62
MAPT P10636 1/20 0.62
THRB P10828 1/20 0.62
ALOX15 P16050 1/20 0.62
NFKB1 P19838 1/20 0.62
THPO P40225 1/20 0.62
RECQL P46063 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
GSR P00390 1/20 0.59
CPB2 Q96IY4 1/20 0.45
SIRT6 Q8N6T7 1/20 0.44
SIRT1 Q96EB6 1/20 0.44
FOLH1 Q04609 1/20 0.43
NOS2 P35228 5/20 0.43
NOS1 P29475 4/20 0.43
NOS3 P29474 3/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetylcysteine SCHEMBL663169 1.00 BLM (0.62) BLMKDM4EMAPTTHRBALOX15
Acetylcysteine SCHEMBL663170 1.00 BLM (0.62) BLMKDM4EMAPTTHRBALOX15
Acetylcysteine SCHEMBL27772811 0.95 KDM4E (0.64) BLMKDM4EMAPTTHRBALOX15
Lysine SCHEMBL18006519 0.89 GSR (0.65) BLMKDM4EMAPTTHRBALOX15
Lysine SCHEMBL18006518 0.89 GSR (0.65) BLMKDM4EMAPTTHRBALOX15
Acetylcysteine SCHEMBL9016357 0.84 ALOX15 (0.70) BLMKDM4EMAPTTHRBALOX15
Acetylcysteine SCHEMBL28342967 0.84 ALOX15 (0.70) BLMKDM4EMAPTTHRBALOX15
Acetylglutamic Acid SCHEMBL11756644 0.84 FOLH1 (0.64) GSRSIRT6SIRT1FOLH1CYP1A2
SCHEMBL21828643 0.83 GSR (0.55) BLMKDM4EMAPTTHRBALOX15
SCHEMBL14957758 0.83 GSR (0.55) BLMKDM4EMAPTTHRBALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4169380-A1 AGRICULTURAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF BACTERIAL DISEASES AND DISORDERS Amazon Agrosciences Ltda (BR) 2023-04-26 EP claimed
US-20210392886-A1 Agricultural Composition for the Treatment and Prevention of Bacterial Diseases and Disorders Instituto Agronômico (IAC) (BR) 2021-12-23 US claimed
EP-2976061-B1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD (BE) 2019-10-16 EP claimed
US-20160279043-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2016-09-29 US claimed
EP-2976061-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS Dentalmed Pharm Holding Ltd. (BE) 2016-01-27 EP claimed
WO-2014147613-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS DENTALMED PHARM HOLDING LTD. (BE) 2014-09-25 WO claimed
US-20140024857-A1 CYSTEINE AMINO-ACID COMPOUND (OR ITS ANALOGUES) USED IN THE DISRUPTION OF MICROBIAL BIOFILMS WHEN TREATING OR PREVENTING DISEASES CAUSED BY PHYTOPATHOGENIC BACTERIA KNOWN TO ATTACK PLANTS OF AGRICULTURAL INTEREST INSTITUTO AGRONOMICO DE CAMPINAS - IAC (BR) 2014-01-23 US claimed
CN-102316730-A Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation TIARA PHARMACEUTICALS INC 2012-01-11 CN claimed
CN-101664384-B N-acetyl-cysteine salt xylitol injection, preparation method and application thereof SIXTH PEOPLE S HOSPITAL OF HANGZHOU 2011-09-14 CN claimed
CN-1874757-B Mucoactive agents for treating a pulmonary disease VECTURA LTD 2011-03-09 CN claimed
CN-101664384-A N-acetyl-cysteine salt xylitol injection, preparation method and application thereof SIXTH PEOPLE S HOSPITAL OF HAN 2010-03-10 CN claimed
EP-0964675-A1 DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT "PHARLYSE", Société Anonyme (LU) 1999-12-22 EP claimed
WO-1998050015-A1 DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT PHARLYSE, SOCIETE ANONYME (LU) 1998-11-12 WO claimed
EP-4333853-A1 METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR Thirona Bio, Inc. (US) 2024-03-13 EP disclosed
CN-117615765-A Methods of treating pulmonary diseases with ALK-5 (TGF beta R1) inhibitors 蒂罗纳生物股份有限公司 2024-02-27 CN disclosed
US-20230130132-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF BONE SCI. BIO LTD. (IL) 2023-04-27 US disclosed
CN-1874757-A Mucoactive agents for treating a pulmonary disease VECTURA LTD (GB) 2006-12-06 CN disclosed
EP-0964675-A1 DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT "PHARLYSE", Société Anonyme (LU) 1999-12-22 EP disclosed
WO-1998050015-A1 DRY POWDER INHALER EXCIPIENT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT PHARLYSE, SOCIETE ANONYME (LU) 1998-11-12 WO disclosed
US-4847282-A Mucolytic acetylcysteine salts GALEPHAR (BE) 1989-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160279043-A1 COMBINATIONS OF N-ACETYL CYSTEINE DERIVATIVES AND CRANBERRY POLYPHENOLS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING PERIODONTAL DISEASES AND PERI-IMPLATITIS SIRT3, NNT, SIRT1 PTGS2 208/4885PTGS1 185/4885BLM 4815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.